GRTS vs. CVM, PASG, ATHA, ATRA, CGTX, JATT, PLX, DTIL, TIL, and ELUT
Should you be buying Gritstone bio stock or one of its competitors? The main competitors of Gritstone bio include CEL-SCI (CVM), Passage Bio (PASG), Athira Pharma (ATHA), Atara Biotherapeutics (ATRA), Cognition Therapeutics (CGTX), JATT Acquisition (JATT), Protalix BioTherapeutics (PLX), Precision BioSciences (DTIL), Instil Bio (TIL), and Elutia (ELUT). These companies are all part of the "biological products, except diagnostic" industry.
CEL-SCI (NYSE:CVM) and Gritstone bio (NASDAQ:GRTS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.
CEL-SCI has a net margin of 0.00% compared to CEL-SCI's net margin of -847.24%. CEL-SCI's return on equity of -147.22% beat Gritstone bio's return on equity.
In the previous week, Gritstone bio had 3 more articles in the media than CEL-SCI. MarketBeat recorded 3 mentions for Gritstone bio and 0 mentions for CEL-SCI. CEL-SCI's average media sentiment score of 0.25 beat Gritstone bio's score of 0.00 indicating that Gritstone bio is being referred to more favorably in the news media.
Gritstone bio received 139 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 69.15% of users gave Gritstone bio an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote.
CEL-SCI has higher earnings, but lower revenue than Gritstone bio. CEL-SCI is trading at a lower price-to-earnings ratio than Gritstone bio, indicating that it is currently the more affordable of the two stocks.
12.1% of CEL-SCI shares are held by institutional investors. Comparatively, 48.5% of Gritstone bio shares are held by institutional investors. 16.2% of CEL-SCI shares are held by company insiders. Comparatively, 4.6% of Gritstone bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Gritstone bio has a consensus target price of $6.33, indicating a potential upside of 557.87%. Given CEL-SCI's higher possible upside, analysts plainly believe Gritstone bio is more favorable than CEL-SCI.
CEL-SCI has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Gritstone bio has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.
Summary
Gritstone bio beats CEL-SCI on 11 of the 16 factors compared between the two stocks.
Get Gritstone bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gritstone bio Competitors List
Related Companies and Tools
